DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute: Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Bench to Bassinet Administrative Coordinating Center.

Date: August 25, 2015.

Time: 12:00 p.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Room 7182, Bethesda, MD 20892

Contact Person: Susan Wohler Sunnarborg, Ph.D. Scientific Review Officer, Office of Scientific Review/DERA, National, Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7182, Bethesda, MD 20892, sunnarborgsw@nhlbi.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and

<table>
<thead>
<tr>
<th>Laboratory Exams</th>
<th># of Patients (Numerator)</th>
<th># Considered (Denominator)</th>
<th>Percent</th>
<th>Area Percent</th>
<th>IHS Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urine Albumin/creatinine Ratio (UACR)</td>
<td>Yes</td>
<td>111</td>
<td>125</td>
<td>89%</td>
<td>110%</td>
</tr>
<tr>
<td>No</td>
<td>14</td>
<td>125</td>
<td>11%</td>
<td>111%</td>
<td>39%</td>
</tr>
<tr>
<td>In patients with UACR:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine albumin excretion - Normal: &lt;30 mg/g</td>
<td>63</td>
<td>111</td>
<td>57%</td>
<td>112%</td>
<td>63%</td>
</tr>
<tr>
<td>Urine albumin excretion - Increased:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30-300 mg/g</td>
<td>30</td>
<td>111</td>
<td>27%</td>
<td>113%</td>
<td>27%</td>
</tr>
<tr>
<td>&gt;300 mg/g</td>
<td>18</td>
<td>111</td>
<td>16%</td>
<td>114%</td>
<td>9%</td>
</tr>
<tr>
<td>In patients age 18 and above with eGFR ≥30, UACR done</td>
<td>108</td>
<td>113</td>
<td>96%</td>
<td>115%</td>
<td>68%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cardiovascular Disease</th>
<th># of Patients (Numerator)</th>
<th># Considered (Denominator)</th>
<th>Percent</th>
<th>Area Percent</th>
<th>IHS Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosed CVD</td>
<td>34</td>
<td>125</td>
<td>27%</td>
<td>116%</td>
<td>37%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tuberculosis Status</th>
<th># of Patients (Numerator)</th>
<th># Considered (Denominator)</th>
<th>Percent</th>
<th>Area Percent</th>
<th>IHS Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB test done (skin or blood)</td>
<td>102</td>
<td>125</td>
<td>82%</td>
<td>117%</td>
<td>49%</td>
</tr>
<tr>
<td>If test done, skin test</td>
<td>102</td>
<td>102</td>
<td>100%</td>
<td>118%</td>
<td>99%</td>
</tr>
<tr>
<td>If test done, blood test</td>
<td>0</td>
<td>102</td>
<td>0%</td>
<td>119%</td>
<td>1%</td>
</tr>
<tr>
<td>If TB test done, positive result</td>
<td>11</td>
<td>102</td>
<td>11%</td>
<td>120%</td>
<td>17%</td>
</tr>
<tr>
<td>If positive TB test, treatment completed</td>
<td>2</td>
<td>11</td>
<td>18%</td>
<td>121%</td>
<td>25%</td>
</tr>
<tr>
<td>If negative TB test, after DM diagnosis</td>
<td>84</td>
<td>91</td>
<td>92%</td>
<td>122%</td>
<td>61%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Combined Outcomes Measures</th>
<th># of Patients (Numerator)</th>
<th># Considered (Denominator)</th>
<th>Percent</th>
<th>Area Percent</th>
<th>IHS Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients meeting ALL of the following criteria:</td>
<td>18</td>
<td>125</td>
<td>14%</td>
<td>123%</td>
<td>20%</td>
</tr>
<tr>
<td>A1c &lt;8%, LDL &lt;100, and mean BP &lt;140/90</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In age 18 and above, patients with both an eGFR and a UACR</td>
<td>109</td>
<td>124</td>
<td>88%</td>
<td>124%</td>
<td>59%</td>
</tr>
</tbody>
</table>

Definitions:

1Known hypertension: Has hypertension listed as an active problem, or three visits with a diagnosis of hypertension ever (prior to the end of the Audit period).

2Increased urine albumin excretion: UACR≥30 mg/g.
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS]

Dated: July 29, 2015.

Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015–19030 Filed 8–3–15; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases: Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Endocrinology Ancillary Studies.

Date: August 13, 2015.

Time: 4:30 p.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Maria E. Davila-Bloom, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 758, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–7637, davila-bloomm@extra.niddk.nih.gov.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Sensitive Obesity.

Date: August 31, 2015.

Time: 1:00 p.m. to 2:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Michele L. Barnard, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 758, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–8898, barnardm@extra.niddk.nih.gov.


Date: October 1, 2015.

Time: 11:00 a.m. to 1:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Najma Begum, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 749, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–8894, begummn@niddk.nih.gov.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; NIDDK: Digestive Diseases Program Projects (P01).

Date: October 14, 2015.

Time: 10:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Najma Begum, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 749, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–8894, begummn@niddk.nih.gov.


Date: October 15, 2015.

Time: 2:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Najma Begum, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 749, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–8894, begummn@niddk.nih.gov.


Date: October 15, 2015.

Time: 2:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Najma Begum, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 749, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–8894, begummn@niddk.nih.gov.


Date: July 28, 2015.

David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015–19026 Filed 8–3–15; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases: Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of meetings of the National Diabetes and Digestive and Kidney Diseases Advisory Council.

The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.


Date: September 9, 2015.

Open: 8:30 a.m. to 12:00 p.m.

Agenda: To present the Director’s Report and other scientific presentations.

Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892.

Closed: 3:45 p.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892.

Contact Person: Brant B. Stanfield, Ph.D., Director, Division of Extramural Activities, National Institutes of Diabetes And Digestive and Kidney Diseases, 6707 Democracy Blvd. Room 715, Msc 5452, Bethesda, MD 20892, (301) 594–8843, stanfibr@niddk.nih.gov.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Advisory Council; Diabetes, Endocrinology and Metabolic Diseases Subcommittee.

Date: September 9, 2015.

Closed: 1:00 p.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892.

Open: 2:00 p.m. to 3:30 p.m.

Agenda: To review the Division’s scientific and planning activities.